Concepts (108)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 8 | 2022 | 315 | 3.440 |
Why?
|
| Myocardial Infarction | 8 | 2022 | 238 | 3.130 |
Why?
|
| Heart Failure | 6 | 2024 | 396 | 2.740 |
Why?
|
| Stroke Volume | 3 | 2024 | 100 | 1.670 |
Why?
|
| Medication Adherence | 5 | 2024 | 245 | 1.640 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2023 | 172 | 1.560 |
Why?
|
| Hospitalization | 6 | 2024 | 808 | 1.510 |
Why?
|
| African Americans | 5 | 2020 | 472 | 1.320 |
Why?
|
| Proprotein Convertase 9 | 2 | 2019 | 2 | 1.260 |
Why?
|
| Cholesterol, LDL | 3 | 2020 | 119 | 1.260 |
Why?
|
| Cardiovascular Diseases | 3 | 2022 | 599 | 1.070 |
Why?
|
| Hypertension | 5 | 2024 | 504 | 1.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2023 | 121 | 0.980 |
Why?
|
| Male | 20 | 2024 | 10106 | 0.930 |
Why?
|
| Natural Language Processing | 1 | 2024 | 58 | 0.880 |
Why?
|
| Humans | 25 | 2024 | 17762 | 0.850 |
Why?
|
| Female | 20 | 2024 | 12740 | 0.830 |
Why?
|
| Aged | 17 | 2024 | 6150 | 0.820 |
Why?
|
| Middle Aged | 14 | 2024 | 7988 | 0.790 |
Why?
|
| United States | 13 | 2024 | 4003 | 0.740 |
Why?
|
| Politics | 1 | 2020 | 12 | 0.720 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 203 | 0.690 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 2 | 0.670 |
Why?
|
| Lipoprotein(a) | 1 | 2019 | 7 | 0.670 |
Why?
|
| Incidence | 7 | 2023 | 1266 | 0.650 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2023 | 755 | 0.640 |
Why?
|
| Stress, Psychological | 1 | 2020 | 141 | 0.640 |
Why?
|
| Nutrition Surveys | 1 | 2019 | 61 | 0.630 |
Why?
|
| Perception | 1 | 2019 | 58 | 0.630 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2019 | 43 | 0.620 |
Why?
|
| Forecasting | 1 | 2019 | 75 | 0.620 |
Why?
|
| Self Report | 2 | 2017 | 253 | 0.610 |
Why?
|
| Cognition Disorders | 1 | 2017 | 31 | 0.580 |
Why?
|
| Genetic Variation | 1 | 2017 | 80 | 0.570 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2020 | 535 | 0.570 |
Why?
|
| Cognition | 1 | 2017 | 83 | 0.550 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 179 | 0.550 |
Why?
|
| Insurance Coverage | 1 | 2017 | 106 | 0.520 |
Why?
|
| Ethnic Groups | 1 | 2019 | 485 | 0.500 |
Why?
|
| Aged, 80 and over | 7 | 2024 | 1923 | 0.500 |
Why?
|
| Risk Factors | 8 | 2023 | 3356 | 0.490 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2020 | 86 | 0.490 |
Why?
|
| Adult | 9 | 2024 | 7678 | 0.480 |
Why?
|
| Continental Population Groups | 1 | 2017 | 302 | 0.480 |
Why?
|
| Retrospective Studies | 8 | 2023 | 2461 | 0.450 |
Why?
|
| Ventricular Function, Left | 2 | 2024 | 51 | 0.420 |
Why?
|
| Age Factors | 4 | 2024 | 918 | 0.400 |
Why?
|
| Sex Factors | 3 | 2024 | 644 | 0.380 |
Why?
|
| Antihypertensive Agents | 2 | 2024 | 161 | 0.350 |
Why?
|
| Pandemics | 2 | 2023 | 287 | 0.350 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2020 | 53 | 0.340 |
Why?
|
| Cohort Studies | 5 | 2023 | 2586 | 0.310 |
Why?
|
| Adolescent | 5 | 2023 | 3685 | 0.310 |
Why?
|
| Phenotype | 2 | 2019 | 151 | 0.300 |
Why?
|
| Prevalence | 3 | 2023 | 886 | 0.300 |
Why?
|
| Young Adult | 4 | 2023 | 2461 | 0.270 |
Why?
|
| California | 2 | 2024 | 2326 | 0.260 |
Why?
|
| Medicare | 3 | 2024 | 205 | 0.250 |
Why?
|
| Disease Progression | 1 | 2024 | 264 | 0.220 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2023 | 19 | 0.220 |
Why?
|
| Diabetic Retinopathy | 1 | 2023 | 18 | 0.220 |
Why?
|
| Prospective Studies | 4 | 2023 | 1279 | 0.220 |
Why?
|
| Retinal Diseases | 1 | 2023 | 17 | 0.210 |
Why?
|
| Acute Disease | 1 | 2022 | 142 | 0.190 |
Why?
|
| Calcium Channel Blockers | 1 | 2020 | 14 | 0.180 |
Why?
|
| Time Factors | 3 | 2020 | 1093 | 0.180 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 710 | 0.170 |
Why?
|
| Rosuvastatin Calcium | 1 | 2019 | 4 | 0.170 |
Why?
|
| Prognosis | 2 | 2020 | 609 | 0.170 |
Why?
|
| Inpatients | 1 | 2020 | 81 | 0.160 |
Why?
|
| Health Status Disparities | 1 | 2020 | 146 | 0.160 |
Why?
|
| Outpatients | 1 | 2020 | 110 | 0.160 |
Why?
|
| Aftercare | 1 | 2019 | 49 | 0.160 |
Why?
|
| Drug Utilization | 1 | 2019 | 128 | 0.160 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 1213 | 0.150 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 153 | 0.150 |
Why?
|
| Neuropsychological Tests | 1 | 2017 | 41 | 0.150 |
Why?
|
| Law Enforcement | 1 | 2017 | 2 | 0.140 |
Why?
|
| Accidents, Traffic | 1 | 2017 | 15 | 0.140 |
Why?
|
| HIV Infections | 1 | 2023 | 696 | 0.140 |
Why?
|
| Biomarkers | 1 | 2017 | 303 | 0.140 |
Why?
|
| Child | 1 | 2023 | 2491 | 0.130 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 151 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 375 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 1330 | 0.110 |
Why?
|
| Comorbidity | 2 | 2020 | 597 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 381 | 0.070 |
Why?
|
| Patient Discharge | 2 | 2019 | 154 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2020 | 1101 | 0.060 |
Why?
|
| Fumarates | 1 | 2023 | 4 | 0.060 |
Why?
|
| Adenine | 1 | 2023 | 8 | 0.060 |
Why?
|
| Tenofovir | 1 | 2023 | 18 | 0.060 |
Why?
|
| Retreatment | 1 | 2020 | 10 | 0.040 |
Why?
|
| Geography | 1 | 2020 | 39 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2019 | 69 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2019 | 237 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2020 | 264 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 719 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 315 | 0.040 |
Why?
|
| European Continental Ancestry Group | 1 | 2020 | 529 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 455 | 0.040 |
Why?
|
| Contrast Sensitivity | 1 | 2017 | 1 | 0.040 |
Why?
|
| Automobile Driving | 1 | 2017 | 10 | 0.030 |
Why?
|
| Alabama | 1 | 2017 | 23 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 129 | 0.030 |
Why?
|
| Independent Living | 1 | 2017 | 22 | 0.030 |
Why?
|
| Health Behavior | 1 | 2019 | 360 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2017 | 1260 | 0.030 |
Why?
|
Concepts
(108)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(13)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->